Anti-PCSK9 Antibody Tafolecimab and Anti-PD-1 Antibody Sintilimab Combined With Neoadjuvant Chemoradiotherapy for pMMR/ MSS Locally Advanced Rectal Cancer : A P

Anti-PCSK9 Antibody Tafolecimab and Anti-PD-1 Antibody Sintilimab Combined With Neoadjuvant Chemoradiotherapy for pMMR/ MSS Locally Advanced Rectal Cancer : A Prospective, Multicenter, Randomized, Open-Label, Parallel-Controlled Trial is a phase 3, randomised interventional study registered as NCT07686796 by Guangdong Provincial People's Hospital, with a registry enrolment figure of 148 participants, started 2027-01-01 and due to reach its primary completion in 2030-01-01. Interventions recorded: Short-course radiotherapy; CAPOX (oxaliplatin/capecitabine); Sintilimab; Tafolecimab. Conditions listed: Local Advanced Rectal Cancer; PD-1 Inhibitor; PCSK9 Inhibitor; RCT; Radiotherapy; Capecitabine; Oxaliplatin. Primary outcome: Complete Response (CR) Rate; Number of Participants with Treatment-Related Adverse Events as Assessed by CTCAE v5.0. Colorectal eligibility wording from the registry: "Histologically confirmed rectal adenocarcinoma, determined to be pMMR (proficient mismatch repair) or MSS (microsatellite stable) by immunohistochemistry and/or genetic testing; clinical stage cT3/T4 or cN+; distal tumor margin ≤ 12 cm from the anal verge; and eligible for surgical resection". Sites: China. No results are recorded here; the registry entry is the source.